A Phase III, Multicenter, Randomized, parallel-group study to asses the efficacy and saftey of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open lable octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.

drug protocol number
CSOM230C2402
drug sponsor
Novartis
drug study
Pasireotide
drug trial site
NGHA-R
drug status
Ongoing
drug phase